A phase 3 open-label trial in 440 Chinese adults found the dulaglutide biosimilar LY05008 met its equivalence margin for HbA1c reduction against reference dulaglutide. PICO summary and expert commentary.
Browsing: Diabetes & Glycaemic Control
A small open-label Spanish RCT found a digital education program added to GLP-1 therapy produced greater HbA1c, weight, and adherence gains than usual care over six months. PICO summary and expert commentary.
A small open-label randomised trial comparing dapagliflozin with insulin glargine as a fourth agent for glycaemic variability in type 2 diabetes inadequately controlled on triple therapy. PICO summary and expert commentary.
A double-blind RCT in 67 children found Ringer’s lactate shortened time to DKA resolution versus 0.9% saline, with less hyperchloraemia. PICO summary and expert commentary.
A phase I/II randomized trial found long-term controlled-release oral GABA (Remygen) did not improve C-peptide, CGM metrics, or HbA1c in men with long-standing type 1 diabetes, and side effects were common. PICO summary and expert commentary.
A single-centre randomised trial of 200 women found metformin matched insulin for glycaemic control in gestational diabetes, with some neonatal outcomes favouring metformin. PICO summary and expert commentary.
A three-arm randomized trial in Texans with uncontrolled type 2 diabetes found that all three self-paced virtual and technology-based self-management programs significantly reduced A1c, with no in-person comparator. PICO summary and expert commentary.
A single-centre Shanghai RCT found a family-support self-management programme raised self-management behaviour scores in type 2 diabetes, while HbA1c and other biochemical markers did not improve significantly. PICO summary and expert commentary.
DIAMONDS is a published protocol for a randomised trial testing a supported diabetes self-management programme in adults with type 2 diabetes and severe mental illness; no results are reported yet. PICO summary and expert commentary.
A single-arm extension found HbA1c was sustained over 30 weeks in adults with type 1 diabetes who switched to inhaled technosphere insulin plus degludec. PICO summary and expert commentary.